Restricted Content
On November 29, 2016, Neuronix Ltd. announced it had filed for clearance from the U.S. Food and Drug Administration (FDA) to market its neuroAD Therapy System, a transcranial stimulation therapy system that includes cognitive training as a treatment for mild to moderate Alzheimer’s disease. The filing was based on the strength of results from a multi-center clinical study on the safety and effectiveness of the system.
The study included 131 participants at nine medical centers in the United States and one in Israel. The researchers evaluated the safety and efficacy of the neuroAD Therapy System in comparison . . .
